Abstracts tagged "immune deficiency"

Abstract Number: 762 • 2016 ACR/ARHP Annual Meeting
Pragmatic Treatment of Patients with Systemic Lupus Erythematosus with Rituximab: Long-Term Effects on Serum Immunoglobulins
Venkat Reddy¹, Lina Martínez-Estupiñán², David A. Isenberg³, Maria J. Leandro³ and Geraldine Cambridge³, ¹Rheumatology, University College Hospital, London, United Kingdom, ²Rheumatology, Gregorio Marañón Hospital, Madrid, Spain, ³Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: B cell depletion therapy based on rituximab is a therapeutic option for refractory disease in patients with Systemic Lupus Erythematosus (SLE). Hypogammaglobulinemia can be…
Abstract Number: 2117 • 2016 ACR/ARHP Annual Meeting
B Cell Phenotype and in Vitro Function in Patients with Rheumatoid Arthritis Developing Low Serum Immunoglobulins after Multiple Cycles of Rituximab
Geraldine Cambridge¹, Rita A. Moura², Venkat Reddy³ and Maria J. Leandro¹, ¹Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ²Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, Lisbon, Portugal, ³Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Repeat treatment with rituximab (RTX) predisposes some patients with rheumatoid arthritis (RA) to develop low levels of serum immunoglobulins (Igs). Understanding B cell function…
Abstract Number: 760 • 2016 ACR/ARHP Annual Meeting
Effects of Type I Interferon Inhibition on Blood Leukocyte Subsets in Patients Treated in a Phase IIb Clinical Study of Anifrolumab in SLE
Geoffrey Stephens¹, Rong Zeng², Xiang Guo², Steve Eck³, Yuling Wu³, Liangwei Wang³, Gabor Illei³ and Wendy White², ¹Cellcion, Clarksburg, MD, ²Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ³MedImmune, LLC, Gaithersburg, MD
Background/Purpose: A Phase IIb randomized controlled study (NCT01753193) was conducted with anifrolumab, a fully human, anti-interferon (IFN)–α receptor (IFNAR1) specific antibody in adults with moderate…
Abstract Number: 539 • 2015 ACR/ARHP Annual Meeting
Quantification of T-Cell Receptor Excision Circles (TREC) from Peripheral Blood in Patients with Inflammatory Polyarthritis of Recent Onset (EPA): Association with Radiographic Joint Damage
Alexandre Osborne¹, Nathalie Carrier², Artur J de Brum-Fernandes³, Patrick Liang³, Ariel Masetto⁴ and Gilles Boire³, ¹Clinical Sciences Program, Université de Sherbrooke, Sherbrooke, QC, Canada, ²Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ³Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: Patients with established Rheumatoid arthritis (RA) present evidence for an exhausted immune system. It is not known whether patients seen at the Early inflammatory…
Abstract Number: 2061 • 2014 ACR/ARHP Annual Meeting
Unexpectedly High Prevalence of Immunoglobulin Deficiency in Fibromyalgia
Xavier Caro and Earl Winter, Fibromyalgia Research and Treatment Center, Northridge, CA
Background/Purpose: It has recently been shown that Fibromyalgia (FM) is commonly associated with clinical evidence of neuropathic pain language, laboratory evidence of small fiber…
Abstract Number: 2195 • 2013 ACR/ARHP Annual Meeting
Expanding The Spectrum Of Recombination Activating Gene-1 Deficiency To Include Early Onset Autoimmunity
Lauren A. Henderson¹, Francesco Frugoni¹, Gregory Hopkins², Helen de Boer², Sung-Yun Pai^2,3, Yu Nee Lee¹, Jolan E. Walter⁴, Melissa M. Hazen¹ and Luigi D Notarangelo^5,6, ¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²Division of Hematology and Oncology, Boston Children's Hospital, Boston, MA, ³Division of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, ⁴Division of Allergy/Immunology, Massachusetts General Hospital for Children, Boston, MA, ⁵Division of Immunology and The Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, MA, ⁶Harvard Stem Cell Institute, Boston, MA
Background/Purpose: We sought to identify the etiology of early onset autoimmunity and T cell lymphopenia in two siblings through genetic and functional studies. Newborn screening…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].